Silexion Therapeutics (SLXN) Competitors $7.04 -0.10 (-1.33%) Closing price 09/4/2025 03:51 PM EasternExtended Trading$7.14 +0.09 (+1.28%) As of 09/4/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. FNCH, AYTU, ABP, AIMD, ATNF, LEXX, EDSA, MBRX, SYBX, and CYCCShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Finch Therapeutics Group (FNCH), Aytu BioPharma (AYTU), Abpro (ABP), Ainos (AIMD), 180 Life Sciences (ATNF), Lexaria Bioscience (LEXX), Edesa Biotech (EDSA), Moleculin Biotech (MBRX), Synlogic (SYBX), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Finch Therapeutics Group Aytu BioPharma Abpro Ainos 180 Life Sciences Lexaria Bioscience Edesa Biotech Moleculin Biotech Synlogic Cyclacel Pharmaceuticals Silexion Therapeutics (NASDAQ:SLXN) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings. Do analysts prefer SLXN or FNCH? Silexion Therapeutics currently has a consensus target price of $75.00, indicating a potential upside of 964.58%. Given Silexion Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Silexion Therapeutics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is SLXN or FNCH more profitable? Silexion Therapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% Finch Therapeutics Group N/A -69.14%-26.92% Do insiders and institutionals have more ownership in SLXN or FNCH? 11.0% of Silexion Therapeutics shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 6.0% of Silexion Therapeutics shares are held by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation & earnings, SLXN or FNCH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/AFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.44 Which has more risk and volatility, SLXN or FNCH? Silexion Therapeutics has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Does the media prefer SLXN or FNCH? In the previous week, Silexion Therapeutics had 4 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 5 mentions for Silexion Therapeutics and 1 mentions for Finch Therapeutics Group. Silexion Therapeutics' average media sentiment score of 0.79 beat Finch Therapeutics Group's score of -1.00 indicating that Silexion Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Silexion Therapeutics Positive Finch Therapeutics Group Negative SummarySilexion Therapeutics beats Finch Therapeutics Group on 7 of the 11 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.23M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8975.9926.43Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-0.199.9310.916.06Net Income-$16.44M-$53.38M$3.29B$266.28M7 Day Performance-3.77%0.63%0.18%-0.32%1 Month Performance-20.49%6.31%6.26%3.44%1 Year Performance-94.00%11.63%51.54%23.11% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion TherapeuticsN/A$7.05-1.3%$75.00+964.6%-94.7%$5.23MN/A0.00N/ANews CoverageGap UpFNCHFinch Therapeutics Group0.5262 of 5 stars$13.00+8.3%N/A-3.9%$20.88MN/A-1.47190Short Interest ↑Gap UpAYTUAytu BioPharma3.9081 of 5 stars$2.29-0.7%$10.00+337.6%-5.4%$20.52M$81M-3.17160Short Interest ↓ABPAbproN/A$0.24-0.9%$4.00+1,546.8%N/A$19.47M$180K0.0015Gap DownAIMDAinos0.329 of 5 stars$4.00+4.2%N/A+19.0%$18.64M$20K-0.8040Short Interest ↑ATNF180 Life Sciences0.3272 of 5 stars$3.08-6.8%N/A+0.8%$18.57MN/A-0.207Gap UpLEXXLexaria Bioscience2.9942 of 5 stars$0.91-13.0%$4.00+338.1%-71.9%$17.86M$615.92K-1.367Negative NewsShort Interest ↑High Trading VolumeEDSAEdesa Biotech1.239 of 5 stars$2.44+0.9%$5.00+104.8%-41.3%$17.19MN/A-1.8520MBRXMoleculin Biotech3.256 of 5 stars$0.56-3.1%$4.00+618.1%-84.3%$16.87MN/A0.0020Analyst RevisionGap DownSYBXSynlogicN/A$1.44-2.7%N/A-1.4%$16.85M$10K-18.0080CYCCCyclacel Pharmaceuticals1.3935 of 5 stars$7.50-0.7%N/A-97.1%$16.79M$40K-0.0114Positive NewsShort Interest ↓ Related Companies and Tools Related Companies Finch Therapeutics Group Alternatives Aytu BioPharma Alternatives Abpro Alternatives Ainos Alternatives 180 Life Sciences Alternatives Lexaria Bioscience Alternatives Edesa Biotech Alternatives Moleculin Biotech Alternatives Synlogic Alternatives Cyclacel Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
